References
- Junghanss C, Marr KA. Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture? Curr Opin Infect Dis 2002;15:347–353.
- Cappellano P, Viscoli C, Bruzzi P, et al Epidemiology and risk factors for bloodstream infections after allogeneic hematopoietic stem cell transplantion. New Microbiol 2007;30:89–99.
- Poutsiaka DD, Price LL, Ucuzian A, et al Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant 2007;40:63–70.
- Mohty M, Jacot W, Faucher C, et al Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17:2168–2177.
- Krüger WH, Bohlius J, Cornely OA, et al Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol 2005;16:1381–1390.
- Momin F, Chandrasekar PH. Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 1995;123:205–215.
- D'Antonio D, Di Bartolomeo P, Iacone A, et al Meningitis due to penicillin-resistant Streptococcus pneumoniae in patients with chronic graft-versus-host disease. Bone Marrow Transplant 1992;9:299–300.
- De Witte T, Novakova I, Branolte J, et al Long-term oral ciprofloxacin for infection prophylaxis in allogeneic bone marrow transplantation. Pharm Weekbl Sci 1987;9:S48–S52.
- De Pauw BE, Donnelly JP, De Witte T, et al Options and limitations of long-term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1990;5:179–182.
- Hurst M, Lamb HM, Scott LJ, et al Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 2002;62:2127–2167.
- Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 2007;35:421–427.
- Gesu GP, Marchetti F, Piccoli L, et al Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003;47:816–819.